| 货号 | CAS号 |
|---|---|
| E129946-5mg | 1291074-87-7 |
| E129946-25mg | 1291074-87-7 |
| 溶解性 | DMSO |
| 存贮条件 | 储存温度-20°C |
| 产品介绍 | ENMD-2076 L-(+)-Tartaric acid 是ENMD-2076的酒石酸，选择性作用于Aurora A和VEGFR(Flt3)，IC50分别为14 nM和1.86 nM，作用于Aurora A比作用于Aurora B选择性高25倍，对VEGFR2/KDR和VEGFR3， FGFR1和FGFR2和PDGFRα作用效果稍弱。Phase 2。 |
| 备注 | ENMD-2076 (L-(+)-Tartaric acid) is the tartaric acid of ENMD-2076, selective activity against Aurora A and VEGFR(Flt3) with IC50 of 14 nM and 1.86 nM, 25-fold more selective for Aurora A than Aurora B and less potent to VEGFR2/KDR and |
| 生化机理 |
ENMD-2076 is a antiangiogenic and Aurora kinase inhibitor with IC50 of 3, 13, 350, 23, 40, 93 and 120 nM for Flt-3, AurA, AurB, Src, KDR/VEGFR2 and FGFR1. |
| 别名 | ENMD-2076 酒石酸盐;ENMD 2076; ENMD2076;(E)-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine,L-(+)-Tartaric acid |
